Advertisement
Research Article

Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

  • Mary F. Kearney mail,

    kearneym@ncifcrf.gov

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Jonathan Spindler,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Wei Shao,

    Affiliation: Advanced Biomedical Computing Center, SAIC, Frederick, Maryland, United States of America

    X
  • Sloane Yu,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Elizabeth M. Anderson,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Angeline O'Shea,

    Affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH Bethesda, Maryland, United States of America

    X
  • Catherine Rehm,

    Affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH Bethesda, Maryland, United States of America

    X
  • Carry Poethke,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Nicholas Kovacs,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • John W. Mellors,

    Affiliation: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    X
  • John M. Coffin,

    Affiliation: Department of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, United States of America

    X
  • Frank Maldarelli

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Published: March 20, 2014
  • DOI: 10.1371/journal.ppat.1004010

About the Authors

Mary F. Kearney, Jonathan Spindler, Sloane Yu, Elizabeth M. Anderson, Carry Poethke, Nicholas Kovacs, Frank Maldarelli
HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America
Wei Shao
Advanced Biomedical Computing Center, SAIC, Frederick, Maryland, United States of America
Angeline O'Shea, Catherine Rehm
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH Bethesda, Maryland, United States of America
John W. Mellors
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
John M. Coffin
Department of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, United States of America

Corresponding Author

Email: kearneym@ncifcrf.gov

Competing Interests

John Mellors is a consultant for Gilead Sciences and owns share options in RFS Pharmaceuticals. This does not alter our adherence to all PLoS Pathogens policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: MFK JWM JMC FM. Performed the experiments: MFK JS SY. Analyzed the data: WS EMA NK. Contributed reagents/materials/analysis tools: MFK FM AOS CR CP. Wrote the paper: MFK JWM JMC FM.